
UniQure Seeks FDA Approval for Huntington’s Gene Therapy After Overcoming Setbacks
UniQure is now awaiting a decision from the FDA on its application for Huntington’s gene therapy, following a challenging year of navigating U.S. regulatory hurdles. This development in the pharma industry could have implications for American healthcare innovation and the treatment of genetic disorders.












